Related references
Note: Only part of the references are listed.Pharmacokinetics of the CYP3A4 and CYP2B6 Inducer Carbamazepine and Its Drug-Drug Interaction Potential: A Physiologically Based Pharmacokinetic Modeling Approach
Laura Maria Fuhr et al.
PHARMACEUTICS (2021)
Drug-induced endocrine blood pressure elevation
Katharina R. Beck et al.
PHARMACOLOGICAL RESEARCH (2020)
Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary
Masoud Jamei et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2020)
Distinct Effects of Inflammation on Cytochrome P450 Regulation and Drug Metabolism: Lessons from Experimental Models and a Potential Role for Pharmacogenetics
Laura M. de Jong et al.
GENES (2020)
Data Digitizing: Accurate and Precise Data Extraction for Quantitative Systems Pharmacology and Physiologically-Based Pharmacokinetic Modeling
Jan-Georg Wojtyniak et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2020)
Application of PBPK Modeling and Simulation for Regulatory Decision Making and Its Impact on US Prescribing Information: An Update on the 2018-2019 Submissions to the US FDA's Office of Clinical Pharmacology
Xinyuan Zhang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Expression of clinically relevant drug-metabolizing enzymes along the human intestine and their correlation to drug transporters and nuclear receptors: An intra-subject analysis
Anja Fritz et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2019)
Assessment of Passive Intestinal Permeability Using an Artificial Membrane Insert System
Philippe Berben et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2018)
Itraconazole induced hypertension and hypokalemia: Mechanistic evaluation
Wesley J. Hoffmann et al.
MYCOSES (2018)
Hypertension
Suzanne Oparil et al.
NATURE REVIEWS DISEASE PRIMERS (2018)
2018 ESC/ESH Guidelines for the management of arterial hypertension
Bryan Williams et al.
EUROPEAN HEART JOURNAL (2018)
Modeling Tolerance Development for the Effect on Heart Rate of the Selective S1P1 Receptor Modulator Ponesimod
Dominik Lott et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin
Nina Hanke et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2018)
The influence of CYP3A5*3 and BCRPC421A genetic polymorphisms on the pharmacokinetics of felodipine in healthy Chinese volunteers
Q. Xiang et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2017)
Coffee inhibition of CYP3A4 invitro was not translated to a grapefruit-like pharmacokinetic interaction clinically
George K. Dresser et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2017)
Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals
Jan-Frederik Schlender et al.
CLINICAL PHARMACOKINETICS (2016)
The Prediction of the Relative Importance of CYP3A/P-glycoprotein to the Nonlinear Intestinal Absorption of Drugs by Advanced Compartmental Absorption and Transit Model
Junichi Takano et al.
DRUG METABOLISM AND DISPOSITION (2016)
Oral Pharmacokinetics of Felodipine in Mexican Healthy Volunteers: Evidence for Interethnic Differences
Jose Carlos Aguilar-Carrasco et al.
INTERNATIONAL JOURNAL OF PHARMACOLOGY (2015)
Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates - An evaluation and case study using GastroPlus™
Aki T. Heikkinen et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2012)
Evaluation of Exposure Change of Nonrenally Eliminated Drugs in Patients With Chronic Kidney Disease Using Physiologically Based Pharmacokinetic Modeling and Simulation
Ping Zhao et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
BDDCS Applied to Over 900 Drugs
Leslie Z. Benet et al.
AAPS JOURNAL (2011)
Immune-related effects in hypertension and target-organ damage
Dominik N. Muller et al.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2011)
Critique of the Two-Fold Measure of Prediction Success for Ratios: Application for the Assessment of Drug-Drug Interactions
Eleanor J. Guest et al.
DRUG METABOLISM AND DISPOSITION (2011)
Physiologically Based Pharmacokinetic Modeling of Intestinal First-Pass Metabolism of CYP3A Substrates with High Intestinal Extraction
Michael Gertz et al.
DRUG METABOLISM AND DISPOSITION (2011)
Pharmacokinetic and Antihypertensive Profile of Amlodipine and Felodipine-ER in Younger Versus Older Patients With Hypertension
Frans H. H. Leenen et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2010)
Impact of the intragastric location of extended release tablets on food interactions
W Weitschies et al.
JOURNAL OF CONTROLLED RELEASE (2005)
Effect of menthol on the pharmacokinetics and pharmacodynamics of felodipine in healthy subjects
A Gelal et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Bergamottin contribution to the grapefruit juice-felodipine interaction and disposition in humans
TC Goosen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Validated assays for human cytochrome P450 activities
RL Walsky et al.
DRUG METABOLISM AND DISPOSITION (2004)
Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: Comparison with grapefruit juice
DG Bailey et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Quinidine and haloperidol as modifiers of CYP3A4 activity: Multisite kinetic model approach
A Galetin et al.
DRUG METABOLISM AND DISPOSITION (2002)
Comparison of the time courses and potencies of the vasodilator effects of nifedipine and felodipine in the human forearm
R van der Lee et al.
BLOOD PRESSURE (2001)
Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients
DG Bailey et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
Grapefruit juice-felodipine interaction in the elderly
GK Dresser et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
Share Paper
